A draft guidance by the US Food and Drug Administration signals the agency’s admission that the data on biosimilar switching is now comprehensive and persuasive. If these draft recommendations  are unchanged in the final guidance document, expensive biosimilar switching studies will no longer be needed for a manufacturer seeking the interchangeability designation. The draft guidance, … Continue reading FDA on Switching Studies to Demonstrate Interchangeability: Don’t Bother, We’re Convinced